About Entrez
Text Version
Entrez PubMed
Overview
Help |
FAQ
Tutorial
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby
Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central
|
|
Items 1 - 4 of 4 |
One page. |
Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP, Eerdekens E, Berry SA, Eerdekens M.
Manhattan Psychiatric Center, New York University School of Medicine, New York, NY 10035, USA. lindemayer@nki.rfmh.org
BACKGROUND: The safety and efficacy of the first long-acting injectable atypical antipsychotic, risperidone, were assessed in stable patients with schizophrenia switched from oral antipsychotic medications. METHOD: Data were collected between July 1, 2001, and October 25, 2002. The study population included patients from clinics, hospitals, and physicians' offices. After a 4-week run-in period, symptomatically stable patients with schizophrenia (DSM-IV) who had been taking haloperidol (N = 46), quetiapine (N = 45), or olanzapine (N = 50) received 25 mg of long-acting risperidone. The oral antipsychotics were continued for 3 weeks after the first injection of long-acting risperidone. Injections were administered every 2 weeks at 25 mg up to a maximum dose of 50 mg for 12 weeks in this multicenter, open-label study. RESULTS: Long-acting risperidone was well tolerated. Of the 141 patients who participated in the study, the most frequently reported adverse events were insomnia (16%), headache (15%), psychosis (11%), and agitation (11%). The mean increase in body weight was 0.4 kg. No other clinically relevant laboratory abnormalities or significant electrocardiogram changes were observed during the 12-week treatment. Extrapyramidal Symptom Rating Scale total scores were reduced during treatment with long-acting risperidone. Improvements in symptoms of schizophrenia were observed with long-acting risperidone at week 4 and continued through the 12-week treatment with significant reductions in total Positive and Negative Syndrome Scale (PANSS) scores at week 8 (-2.5, p <.01) and week 12 (-3.9, p <.001). At endpoint, 37% (50/135) of these stable patients were rated as clinically improved (> or = 20% decrease in PANSS total scores). CONCLUSIONS: Switching treatment from oral antipsychotics to long-acting risperidone without an intervening period of oral risperidone was safe and well tolerated. Long-acting risperidone also significantly reduced the severity of symptoms in these stable patients with schizophrenia.
Publication Types:
- Clinical Trial
- Multicenter Study
PMID: 15323593 [PubMed - indexed for MEDLINE]
Intentional overdose with tiagabine: An unusual clinical presentation.
Cantrell FL, Ritter M, Himes E.
California Poison Control System, San Diego Division, San Diego, California, USA; School of Pharmacy, University of California San Francisco, San Francisco, California, USA.
Tiagabine (Gabitril((R))) is a unique anticonvulsant that is prescribed for a variety of psychiatric disorders. We report a case of intentional self-poisoning with tiagabine. A 46-year-old woman was brought to the Emergency Department after being found confused and nonverbal while wandering in a field. Eighteen tablets (72 mg) of her tiagabine prescription were missing. Remarkable findings on initial examination were facial grimacing, flexure posturing of both upper extremities, and 7-mm, reactive pupils. She was uncommunicative and unable to follow commands. Vital signs, blood chemistries and a head CT scan were normal. Urine toxicology screening was negative. An extrapyramidal reaction was suspected and diphenhydramine 50 mg was administered without effect. Lorazepam 2 mg was given with significant improvement. She was admitted for observation and all symptoms resolved within 12 h of admission. Tiagabine overdose causes an unusual array of neurological symptoms, many similar to reported adverse effects during therapeutic use.
PMID: 15388215 [PubMed - in process]
Algal toxins or copper poisoning--revisiting the Palm Island "epidemic".
Prociv P.
Publication Types:
PMID: 15377259 [PubMed - in process]
Outbreak of cyclosporiasis associated with snow peas--Pennsylvania, 2004.
Centers for Disease Control and Prevention (CDC).
During June-July 2004, public health officials in Pennsylvania were notified of cases of the parasitic disease cyclosporiasis among persons associated with a residential facility (e.g., residents, staff, and volunteers). CDC confirmed the diagnosis of Cyclospora cayetanensis infection by examining stool specimens from multiple patients. By early July, local public health officials had been notified of approximately 50 potential cases of cyclosporiasis associated with the facility; onsets of illness were from early June through early July. This report describes the findings of the epidemiologic and traceback investigations, which determined the cases were linked to consumption of raw Guatemalan snow peas at five special events, for which food was prepared by the facility staff, from late May through late June. This is the first documented outbreak of cyclosporiasis linked to snow peas. The Food and Drug Administration (FDA) and CDC are working with Guatemalan officials to determine the sources of the snow peas and possible modes of contamination.
PMID: 15385921 [PubMed - indexed for MEDLINE]
|